세계의 유전체학 시장(2023-2030년)

Market Overview

Global Genomics Market reached US$ 27.9 billion in 2022 and is expected to reach US$ 115.4 billion by 2030, growing with a CAGR of 18.7% during the forecast period 2023-2030.

The global genomics market witnessing significant growth and transformations in recent years, with various factors influencing its dynamics. Government investments in identifying and characterizing all the genes and functional elements of all organisms will continue to drive and boost the global genomics market. The global industry is placing increasing emphasis on reducing its impact.

Genomics in health examines the particular molecular mechanisms and the interplay of this molecular information and health interventions and environmental factors in the identification of the disease. Genomics is applied for real-time PCR, mutational analysis, and others. Similarly, North America dominates the genomics market, capturing the largest market share owing to the increased adoption of genomics and technological advancements.

Owing to the factors such as increasing research activities, increasing adoption of genomics, rising demand for genomic testing and analysis, increasing adoption of genomics for pharmaceutical developments, rising demand for personalized medicine, and technological advancements are expected to drive the global genomics market over the forecast period.

Market Dynamics

Increasing Adoption of Genomics in Pharmaceutical Developments is Expected to Drive the Growth of the Market

The increasing adoption of genomics in pharmaceutical developments is expected to drive the genomics market growth over the forecast period. According to the National Institute of Health (NIH), genomics has been used as a tool for accelerating drug development for over 20 years. Various conceptual approaches and techniques assist target identification, target prioritization, and tractability, as well as the prediction of outcomes from pharmacological perturbations.

Many genomic-based tests are used in the understanding and management of the disease in a better way. For instance, on November 16, 2022, Strand Life Sciences, genomics-based research and diagnostics company, launched a new line of genomic-based tests for preventive wellness, Strand Genomic Wellness. It aims to help individuals understand and manage their disease better.

Moreover, genomics also enables researchers to identify and validate potential drug targets by studying the genetic mutations and variations associated with particular diseases. This research knowledge helps pharmaceutical companies develop more precise therapies that target the underlying causes of specific diseases with genomic medicine.

For instance, on September 29, 2022, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year, 2.5 times the throughput of prior sequencers, greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives.

Increasing Demand for Precision Medicine is Also Expected to Drive the Growth of the Market

The increasing demand for precision medicine is expected to drive the genomics market over the forecast period. Genomics helps in advancing precision medicine and improving patient health and wellness. Precision medicine allows healthcare providers to develop personalized treatment options which are specifically tailored to each patient's genetic profile. Using genomics in precision medicine improves treatment efficacy and reduces adverse effects, leading to better patient outcomes.

For instance, on August 16, 2023, the Duke University Health System and School of Medicine launched a precision medicine study called OneDukeGen that will integrate comprehensive genomic data and clinical information to foster a deeper understanding of hereditary disease susceptibilities. The study aims to recruit more than 100,000 consented Duke patients to participate in the research.*

Furthermore, genomic profiling of tumors has revolutionized the better cancer treatment. By understanding the genetic mutations, genomics helps to develop more effective treatment options by using the next generation technologies by measuring the gene function of individual patients. This further drives the growth of the market.

For instance, on April 12, 2023, Precision medicine company Function Oncology officially launched a genomics platform with the goal of revolutionizing the future of targeted cancer treatment by developing a CRISPR-powered, personalized functional genomics platform. Rather than relying on traditional gene sequencing, the San Diego-based startup is committed to advancing the next generation of targeted cancer treatments by measuring gene function at the level of individual patients.

Stringent Regulatory Challenges Will Hamper the Market's Growth

The stringent regulatory challenges associated with genomics are expected to hamper the growth of the market over the forecast period. The genomic data is highly sensitive and very personal. Regulations governing data privacy and security, such as the General Data Protection Regulation (GDPR) in Europe or the Health Insurance Portability and Accountability Act (HIPAA) in the United States, require strict adherence to safeguard the patient information to prevent the unauthorized access.

Additionally, regulatory standards also ensure the quality and accuracy of genetic testing methodologies and laboratory processes by using genomics. This is crucial to avoid false results and misinterpretations that could lead to incorrect medical decisions. Regulatory authorities often require evidence of the clinical validity and utility of genetic tests before they can be used in medical practice. This ensures that the tests provide reliable and actionable information.

For more details on this report - Request for Sample

Segment Analysis

The global genomics treatment market is segmented based on application & technology, Products and Services, End-user, and region.

Based on Application and Technology, the Functional Genomics Segment is Estimated to Contribute 34.3% to the Growth of the Global Market

The functional genomics segment is expected to hold the largest market share over the forecast period. Functional genomics explains how genes and intergenic segments of the genome contribute to different metabolic pathways (gene expression patterns). The main objective of functional genomics is to resolve how the individual segment of an organism work together to produce a particular phenotype Functional genomics allows researchers to concentrate on the molecular mechanisms by underlying various diseases mainly rare diseases.

For instance, according to the European Bioinformatics Institute, functional genomics focuses on the dynamic expression of gene products in a specific context at a specific developmental stage or during a disease. In functional genomics, current knowledge of gene function is used to develop a model linking genotype to phenotype.

Moreover, functional genomics also plays an important role in the process of identifying potential drug targets by understanding the drug interactions with the body's molecular processes. This process further helps in drug development and discovery by providing detailed insights into the drug's efficacy and potential side effects. Functional genomics also enables researchers to understand how genes interact within networks to drive specific outcomes.

Geographical Penetration

North America Accounted for Approximately 38.2% of the Market Share in 2022, Owing to the Increasing Adoption of Genomic and Technological Advancements

North America is expected to hold the largest market share over the forecast period owing to the increasing adoption of genomics and technological advancements. The region is very well known for its advanced healthcare infrastructure, which rapidly performs research activities by using genomics. Their wide adoption of genomics helps in the clinical practice for pharmaceutical developments and their research activities.

Moreover, North America is at the forefront of the development of technological advancements in genomics. Many major genomic players in the region are focussing on the development of technologically advanced genomic assays such as Next Generation Sequencing (NGS) based assays and more, further contributing to the market dominance in the region.

For instance, on April 12, 2023, Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced the launch of NEW CentoGenome, an enhanced Next Generation Sequencing (NGS)-based assay. Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options.

Competitive Landscape

The major global players in the genomics market include Agilent Technologies, Bio-Rad Laboratories, Inc., BGI Genomics, Color Genomics, Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina, Inc., and Myriad Genetics, Inc., among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global genomics market. During the pandemic, many research activities related to drug developments using genomics have been temporarily postponed due to the redirected focus on the COVID-19 pandemic and its related restrictions.

With the onset of the pandemic in early 2020, the applications of genomics are most widely used in COVID-19 and other infectious disease diagnosis. Still, many infectious diseases are able to cure by the power of pathogen genomics. For instance, on May 20, 2023, WHO and its partners announced that they launched a global network to help protect people from infectious disease threats through the power of pathogen genomics.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as genomic components and technologies. Movement restrictions and border closures delayed shipments and caused transportation delays. Additionally, some countries faced shortages of genomic components due to disruptions in their supply chain networks.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global genomics market. The conflict disrupted the availability of the components and technologies due to supply chain disruption, which are used in genomics research and diagnostics, this further delays the research projects and the product developments.

By Application & Technology

• Functional Genomics

Transfection

Real-Time PCR

RNA Interference

Mutational Analysis

SNP Analysis

Microarray Analysis

• Epigenomics

Bisulfite Sequencing

Chromatin Immunoprecipitation (CHIP & CHIP-Seq)

Methylated DNA Immunoprecipitation (MEDIP)

High-Resolution Melt (HRM)

Chromatin Accessibility Assays

Microarray Analysis

• Pathway Analysis

Bead-Based Analysis

Microarray Analysis

Real-Time PCR

Proteomics Tools

• Biomarker Discovery

Mass Spectrometry

Real-Time PCR

Microarray Analysis

Statistical Analysis

Bioinformatics

DNA Sequencing

• Others

By Products and Services

• Products

Instruments/Systems/Software

Consumables & Reagents

• Services

NGS-Based Services

Core Genomics Services

Biomarker Translation Services

Computational Services

Others

By End-User

• Clinical Research
• Academic & Government Institutes
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Others

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On July 18, 2023, Genomic Vision, a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce the launch of its new service, HexaCard. HexaCard is an application of Genomic Vision's proprietary Molecular Combing Technology (MCT) that offers precise visualization and measurement of individual DNA molecules. HexaCard aims to consolidate multiple technologies used in assessing engineered genome modifications, offering a streamlined, one-stop-shop solution for the cell and gene therapy (CGT), and biomanufacturing industries. By combining six analytical parameters into a single assay, Genomic Vision's HexaCard service offers a range of advantages in bioproduction and CGT applications.
• On July 12, 2023, Illumina, Inc. ILMN recently announced the launch of the latest version of DRAGEN software, DRAGEN 4.2, for analysis of next-generation sequencing (NGS) data. DRAGEN 4.2 is expected to expand accuracy combined with its flexibility and scalability to enable efficient workflows and extract meaningful insights from genomic data.
• On April 25, 2023, Apollo Hospitals announced the expansion of the Apollo Genomics Institute with the launch of a new facility in Chennai. This is the third facility for the healthcare major, which already has genomic institutes in Mumbai and Delhi.
• On September 29, 2022, Neogen Corporation launched the new Encompass platform for bovine genomic results management and visualization. This innovative new data management solution will allow Igenity customers to gain greater insight into their data and maximize the benefits of genomic testing.

DataM Intelligence Opinion:

According to the DataM Intelligence, the genomics market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increased adoption in various sectors including the pharmaceutical sector. Genomic testing and analysis plays a very crucial role in this market. Their wide applications and advanced technologies expected to drive the market in the coming years. The genomics also plays an important role for the development of personalized medicines. Moreover, applications of genomics in rare disease diagnosis helps to rise the market in upcoming years.

Why Purchase the Report?

• To visualize the global genomics market segmentation based on application and technology, Products and Services, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of genomics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global genomics market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Application & Technology
• 3.2. Snippet by Products and Services
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Adoption of Genomics in Pharmaceutical Developments
    • 4.1.1.2. Increasing Demand for Genomic Testing and Analysis
  • 4.1.2. Restraints
    • 4.1.2.1. Stringent Regulatory Challenges
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine Conflict Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Application & Technology

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
  • 7.1.2. Market Attractiveness Index, By Application & Technology
• 7.2. Functional Genomics *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Transfection
  • 7.2.4. Real-Time PCR
  • 7.2.5. RNA Interference
  • 7.2.6. Mutational Analysis
  • 7.2.7. SNP Analysis
  • 7.2.8. Microarray Analysis
• 7.3. Epigenomics
  • 7.3.1. Bisulfite Sequencing
  • 7.3.2. Chromatin Immunoprecipitation (CHIP & CHIP-Seq)
  • 7.3.3. Methylated DNA Immunoprecipitation (MEDIP)
  • 7.3.4. High-Resolution Melt (HRM)
  • 7.3.5. Chromatin Accessibility Assays
  • 7.3.6. Microarray Analysis
• 7.4. Pathway Analysis
  • 7.4.1. Bead-Based Analysis
  • 7.4.2. Microarray Analysis
  • 7.4.3. Real-Time PCR
  • 7.4.4. Proteomics Tools
• 7.5. Biomarker Discovery
  • 7.5.1. Mass Spectrometry
  • 7.5.2. Real-Time PCR
  • 7.5.3. Microarray Analysis
  • 7.5.4. Statistical Analysis
  • 7.5.5. Bioinformatics
  • 7.5.6. DNA Sequencing
• 7.6. Others

8. By Products and Services

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
  • 8.1.2. Market Attractiveness Index, By Products and Services
• 8.2. Products *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.2.3. Instruments/Systems/Software
  • 8.2.4. Consumables & Reagents
• 8.3. Services
  • 8.3.1. NGS-Based Services
  • 8.3.2. Introduction
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.4. Core Genomics Services
• 8.5. Biomarker Translation Services
• 8.6. Computational Services
• 8.7. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Clinical Research
• 9.3. Academic & Government Institutes
  • 9.3.1. Introduction
  • 9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.4. Hospitals & Clinics
• 9.5. Pharmaceutical & Biotechnology Companies
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Russia
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Agilent Technologies *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Bio-Rad Laboratories, Inc.
• 12.3. BGI Genomics
• 12.4. Color Genomics, Inc
• 12.5. Danaher Corporation
• 12.6. Eurofins Scientific
• 12.7. F. Hoffmann-La Roche Ltd
• 12.8. GE Healthcare
• 12.9. Illumina, Inc.
• 12.10. Myriad Genetics, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us